Rupatadine: global safety evaluation in allergic rhinitis and urticaria

References

• Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl 5):S147–S334.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaled NA, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis (ARIA) update (in collaboration with GA2LEN). Allergy. 2006;61:1086–1096.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8–160.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887.
   PubMed Web of Science ®Google Scholar
• Church MK, Máspero JF, Maurer M, et al. The scope of pharmacological and clinical effects of modern antihistamines, with a special focus on rupatadine. Wao J. 2010;3(Suppl 4):S1–S16.
   Google Scholar
• Muñoz-Cano R, Valero A, Roca-Ferrer J, et al. Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients. Am J Rhinol Allergy. 2013;27:e48–52.
   PubMed Web of Science ®Google Scholar
• Muñoz-Cano R, Valero A, Izquierdo I, et al. Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over design. Allergy Asthma Clin Immunol. 2013;9:43.
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459–466.
   PubMed Web of Science ®Google Scholar
• Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–1150.
   PubMed Web of Science ®Google Scholar
• Brożek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010;126:s466-476.
   PubMed Web of Science ®Google Scholar
• Mullol J. Positioning of antihistamines in the allergic rhinitis and its impact on asthma (ARIA) guidelines. Clin Exper Allergy Rev. 2012;12:17–26.
   Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70:1–24.
   PubMed Web of Science ®Google Scholar
• Nettis E, Delle Donne P, Di Leo E, et al. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother. 2013;14:1807–1813.
   PubMed Web of Science ®Google Scholar
• Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280:114–121.
   PubMed Web of Science ®Google Scholar
• Merlos M, Balsa D, Giral M, et al. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues. Methods Find Exp Clin Pharmacol. 1997;19(Suppl.A):148.
   Google Scholar
• Van Den Anker-Rakhmanina NY. Rupatadine. Curr Opin Antiinflamm Immumomodul Invest Drugs. 2000;2:127–132.
   Google Scholar
• Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine, a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003;39:451–468.
   PubMed Web of Science ®Google Scholar
• Giral M, Balsa D, Ferrando R, et al. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy. 1998;53(Suppl.):131.
   PubMed Web of Science ®Google Scholar
• Merlos M, Ferrando R, Giral M, et al. Effect of topical rupatadine in experimental conjunctivitis in guinea pigs: macroscopic evaluation of ocular lesions. J Allergy Clin Lmmunol. 2001;107(Suppl. 2):S310.
   Google Scholar
• Queralt M, Merlos M, Giral M, et al. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res. 1996;39:12–18.
   Web of Science ®Google Scholar
• Queralt M, Brazis P, Merlos M, et al. lnhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res. 1998;44:49–55.
   Web of Science ®Google Scholar
• Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-I. Lnflamm Res. 2000;49:355–360.
   PubMed Web of Science ®Google Scholar
• Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in Guinea pigs. Methods Find Exp Clin Pharmacol. 1996;18(Suppl.B):140.
   Google Scholar
• Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in Guinea pigs. Methods Find Exp Clin Pharmacol. 1996;18(Suppl.B):140.
   Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(Suppl 87):5–28.
   PubMed Web of Science ®Google Scholar
• Barrón S, Ramis I, Merlos M. Rupatadine inhibits the inflammatory component of allergic response: cytokine release, adhesion molecule expression and inflammatory cell recruitment. 23rd EAACI Congress, 12–16 June 2004, Amsterdam.
   Google Scholar
• Merlos M, Ramis I, Balsa D, et al. Inhibitory effect of rupatadine on TNF-α release from human monocytes and mast cell line HMC-1. J Allergy Clin Lmmunol. 2000;105(Suppl. 1):S62.
   Google Scholar
• Merlos M, Giral M, Balsa D, et al. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized Guinea pigs. J Allergy Clin Lmmunol. 1998;101(Suppl. 1):S218.
   Google Scholar
• Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol. 1997;19(Suppl.A):189–203.
   PubMedGoogle Scholar
• Barrón S, Roman J, Michelena P, et al. Rupatadine inhibits cytokine production and NF-kB activity by histamine H1 receptor-dependent mechanism. Rev Rinol. 2006;6:18.
   Google Scholar
• Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production. Allergy Clin Immunol Int. 2005;1(Suppl. 1):427.
   Google Scholar
• Curtin ML. Current status of platelet-activating factor antagonists. Exp Opin Ther Patents. 1998;8:703–711.
   Web of Science ®Google Scholar
• Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010;151:38–45.
   PubMed Web of Science ®Google Scholar
• Ramis I, Giral M, Ferrando R, et al. Inhibition of PAF- and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy. 2000;55(Suppl. 63):94–95.
   PubMed Web of Science ®Google Scholar
• Alevizos M, Karagkouni A, Vasiadi M, et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol. 2013;111:542–547.
   PubMed Web of Science ®Google Scholar
• Muñoz-Cano R, Torres Atencio I, Ainsua E, et al. Effects of rupatadine on platelet activating factor (PAF) induced human mast cell degranulation compared with desloratadine and levocetirizine. J Allergy Clin Immunol. 2012;129(Suppl 2):AB122.
   Web of Science ®Google Scholar
• Muñoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, et al. Effects of rupatadine on Platelet activating factor (PAF)-induced human mast cell degranulation compared with desloratadine and levocetirizine (The MASPAF study). J Investig Allergol Clin Immunol. Forthcoming 2016.
   PubMed Web of Science ®Google Scholar
• Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol. 2010;163:1330–1332.
   PubMed Web of Science ®Google Scholar
• Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem. 2004;4:923–933.
   PubMed Web of Science ®Google Scholar
• Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006;7:1989–2001.
   PubMed Web of Science ®Google Scholar
• Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2008;18:57–68.
   Google Scholar
• Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67:457–474.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics (SPC). Rupafin 10mg tablets; [cited2016 Apr]. Available from: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1129-001-001_22042015104040.pdf.
   Google Scholar
• Summary of product characteristics. Rupafin 1mg/ml oral solution; cited 2016Mar. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1424669527506.pdf.
   Google Scholar
• Valle M, Estevez J, Martial LC, et al. Application of population pharmacokinetic modelling and simulation in the design of the optimal dose regime of rupatadine in 2–5 year old children. Clin Transl Allergy. 2014;4(Suppl 1):P39.
   PubMedGoogle Scholar
• Solans A, Izquierdo I, Donado E, et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady state levels: a randomized, open-label, twoway, crossover, phase I study. Clin Ther. 2008;30:1639–1650.
   PubMed Web of Science ®Google Scholar
• Solans A, Carbó ML, Peña J, et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther. 2007;29:900–908.
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Pareds I, Lurigados C, et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2000;55:275.
   Google Scholar
• Eloy P, Tobback L, Imschoot J. Rupatadine improves health related quality of life and severity of allergic rhinitis in a Belgian cohort of 2,800 patients. Allergy. 2012;67(Suppl s96):331.
   Google Scholar
• Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004;50:311–321.
   PubMed Web of Science ®Google Scholar
• Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014;23(3):87–95.
   PubMedGoogle Scholar
• Barbanoj MJ, Garcia-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp. 2006;21(1):13–26.
   PubMed Web of Science ®Google Scholar
• García-Gea C, Ballester MR, Martínez J, et al. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Br J Clin Pharmacol. 2010;69:663–674.
   PubMed Web of Science ®Google Scholar
• Vuurman E, Theunissen E, Van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol Clin Exp. 2007;22(5):289–297.
   PubMed Web of Science ®Google Scholar
• Maiti R, Rahman J, Jaida J, et al. Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg. 2010;136:796–800.
   PubMed Web of Science ®Google Scholar
• Maiti R, Jaida J, Raghavendra BN, et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol. 2011;10:1444–1450.
   PubMed Web of Science ®Google Scholar
• Lu HR, Hermans AN, Gallacher DJ. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torssades de Pointes? Br J Pharmacol. 2012;166(4):1490–1502.
   PubMed Web of Science ®Google Scholar
• DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. 1999;21(2):281–295.
   PubMed Web of Science ®Google Scholar
• Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelines. Br J Clin Pharmacol. 2010;69:401–410.
   PubMed Web of Science ®Google Scholar
• Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: a randomized, double-blind, placebo- controlled study. Pediatr Allergy Immunol. 2013;24:144–150.
   PubMed Web of Science ®Google Scholar
• Valero A, De La Torre F, Castillo JA, et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009;32:33–42.
   PubMed Web of Science ®Google Scholar
• Caballero R, Valenzuela C, Longobardo M. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol. 1999;128:1071–1081.
   PubMed Web of Science ®Google Scholar
• Lukat K, Rivas P, Roger A, et al. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J Asthma Allergy. 2013;6:31–39.
   PubMedGoogle Scholar
• Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronics spontaneous urticaria in children aged 2–11 years. Pediatr Allergy Immunol. 2016;27:55–61.
   PubMed Web of Science ®Google Scholar
• Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013;29:1539–1551.
   PubMed Web of Science ®Google Scholar
• Fantin S, Maspero J, Bisbal C, et al. A 12-week placebo-controlled study of rupatadine 10mg once daily comparative with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008;63(7):924–931.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. 2007;62:539–546.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17:223–228.
   PubMed Web of Science ®Google Scholar
• Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010;104:86–92.
   PubMed Web of Science ®Google Scholar
• Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol. 2016;96:56–59.
   PubMed Web of Science ®Google Scholar
• Vlastarakos PV, Manolopoulos L, Ferekidis E, et al. Treating common problems of the nose and throat in pregnancy: what is safe? Eur Arch Otorhinolaryngol. 2008;265:499–508.
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Taubel J, Ferber G, et al. Rupatadine pharmacokinetics in Japanese healthy volunteers after single and repeated oral doses of 10, 20 and 40 mg. Wao J. 2016;9(Suppl 1):A202.
   Google Scholar
• Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203–2217.
   PubMed Web of Science ®Google Scholar
• Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105:S622–627.
   PubMed Web of Science ®Google Scholar
• Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol. 2003;111:770–776.
   PubMed Web of Science ®Google Scholar
• McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. 2008;23(7):555–570.
   PubMed Web of Science ®Google Scholar
• Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinology. 1999;13:235–243.
   PubMedGoogle Scholar
• Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children. Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009;69:2541–2576.
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5mg in seasonal allergic rhinitis patients. Allergy. 2009;64:158–165.
   PubMed Web of Science ®Google Scholar
• González-Núñez V, Valero A, Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf. 2013;12:445–453.
   PubMed Web of Science ®Google Scholar
• Saint-Martin F, Dumur JP, Pérez I, et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10mg), a new PAF and H1 receptor specific histamine antagonist, to loratadine 10mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:34–40.
   PubMed Web of Science ®Google Scholar
• Guadaño EM, Serra-Batlles J, Meseguer J, et al. Rupatadine 10mg and ebastine 10mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59:766–771.
   PubMed Web of Science ®Google Scholar
• Martinez-Cócera C, De Molina M, Marti-Guadaño E, et al. Rupatadine 10mg and cetirizine 10mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Lnvestigat Allergol Clin Immunol. 2005;15:22–29.
   PubMed Web of Science ®Google Scholar